- Conditions
- Menkes Disease, Occipital Horn Syndrome, Unexplained Copper Deficiency
- Interventions
- Copper Histidine
- Drug
- Lead sponsor
- Cyprium Therapeutics, Inc.
- Industry
- Eligibility
- Up to 80 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced May 22, 2026, 12:01 AM EDT